Active Biotech’s drug for the treatment of MS, SAIK-MS, is currently in clinical Phase II, where the efficacy is verified on MS patients. The ongoing study is a multi-center study where 180 patients are planned to be included from England, Holland, Russia and Sweden.
In the area of development of orally active drugs for the treatment of MS, Active Biotech has consequently the furthest advanced project of all companies internationally.
Active Biotech estimates, that from gaining positive results during the pre-clinical optimisation phase, it takes approximately five years before clinical studies on MS patients potentially can be performed.
The market for MS drugs is estimated to 2.3 billion US dollar (UBS Warburg April 2001) distributed among Schering, Biogen, Serono and Teva. All these companies market injectable drugs though, which show a limited effect on the disease MS.
*Medivir 29 May 2002
Lund 31 May 2002
Active Biotech AB (publ)
Sven Andréasson
President & CEO
Active Biotech is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects (clinical trials phase II) include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50
e-mail info@activebiotech.com